1000731736.jpg
1000731797.jpg
Compare these two bone marrow biopsy report
analyse_media
analyse_media
Reading File
Finding Sources
Finding Sources
Searching PubMed
"myelodysplastic syndrome" AND "hypocellular"
Comparison of the Two Bone Marrow Biopsy Reports (Patient: Khursheed Ahmed, SKIMS Soura)
| Parameter | Report 1 (Earlier) – Lab No. S-4507/26, dated 06/06/26 | Report 2 (Later) – Lab No. S-6770/26, dated 08/08/26 |
|---|---|---|
| Age/Sex | 50 Y/M | 51 Y/M |
| MRD No. | 4190123 | 4266145 |
| Gross | 2 grey-brown bony bits, 0.7 cm & 1.4 cm | 2 grey-brown bony bits, 1.1 cm & 0.3 cm |
| Cellularity | Hypercellular for age | Hypocellular |
| Erythropoiesis | Normoblastic to mildly megaloblastic, erythroid hyperplasia with mild dysplasia | Normoblastic, with few dysplastic and megaloblastic forms (no hyperplasia mentioned) |
| Myelopoiesis | All stages of maturation present, no suppression noted | All stages present but suppressed |
| Megakaryocytes | Adequate, no dysplasia mentioned | Reduced, with dysplastic forms seen |
| Blasts | Not quantified; "no abnormal cells/clusters seen" | 2-3% of total marrow cellularity (explicitly quantified) |
| Advice/Note | Correlate with clinical and aspiration details | Correlate with clinical, aspirational and biochemical details |
| Reporting Consultant | Dr. Rukhsana Akhter | Prof. Dr. Rumana Makhdoomi |
Key Interpretation
There is a clear evolution between the two biopsies, taken roughly two months apart:
-
Cellularity has flipped - from hypercellular-for-age (June) to hypocellular (August). This is the single most striking change and suggests either progressive marrow failure, an evolving clonal process, or a treatment/drug effect (e.g., chemotherapy, immunosuppressive therapy) suppressing hematopoiesis between the two samples.
-
Dysplasia has become more widespread (trilineage). The earlier report showed only mild erythroid dysplasia with an otherwise unremarkable myeloid and megakaryocytic series. The later report shows dysplastic changes extending to the megakaryocytic line as well (reduced, dysplastic megakaryocytes), plus suppressed myelopoiesis - a pattern more in keeping with a myelodysplastic process rather than a purely reactive/nutritional megaloblastic picture.
-
Blasts are now explicitly quantified (2-3%). This is below the ≥5% threshold used for a diagnosis of MDS with excess blasts, and far below the 20% threshold for acute leukemia, so it does not by itself establish a leukemic transformation. However, its appearance alongside new megakaryocytic dysplasia and a hypocellular marrow is a meaningful change from the first report, where no abnormal cells were identified at all.
-
Combined picture: Hypocellular marrow with trilineage dysplastic features and a mildly increased blast fraction raises the differential of hypoplastic myelodysplastic syndrome (MDS) versus aplastic anemia with early clonal/dysplastic evolution, as opposed to the first sample, which looked more like a hypercellular marrow reacting to a nutritional deficiency (vitamin B12/folate-type megaloblastic change) with only mild dysplasia. Per standard hematopathology teaching, hypocellular marrow occurs in a minority (10-15%) of MDS cases and is notoriously difficult to distinguish from aplastic anemia in older patients, which is exactly why both reports advise clinical/aspirate (and now biochemical) correlation - Henry's Clinical Diagnosis and Management by Laboratory Methods.
-
Discrepancy to flag: The two reports carry different MRD numbers (4190123 vs 4266145) and a one-year difference in stated age despite only a two-month gap between collection dates. This may simply reflect re-registration at the hospital, but it is worth clarifying with the treating physician/records department to confirm both samples truly belong to the same patient before drawing firm clinical conclusions.
What this means clinically
The trend (hypercellular with mild reactive-type erythroid dysplasia → hypocellular with trilineage dysplasia and a nascent blast population) is concerning for disease progression and warrants urgent correlation with:
- Peripheral blood counts/smear (looking for cytopenias, dysplastic circulating cells)
- Bone marrow aspirate cytogenetics/FISH and molecular (MDS mutation panel)
- Vitamin B12/folate levels (to exclude a resolving nutritional megaloblastic component from the first sample)
- Clinical history of any new medications, chemotherapy, or toxin exposure between June and August that could explain the drop in cellularity
I did not find recent (last 2-3 years) systematic reviews/meta-analyses that specifically contradict this interpretation; current literature (e.g., the 2024 Lancet Haematology consensus classification for MDS, PMID 39393368, and the 2023 MDS update, PMID 37288607) reinforces that hypocellular marrow with multilineage dysplasia and blast percentages below 5% still requires close monitoring since these cases behave heterogeneously and can evolve.
If you can share the aspirate smear findings or any flow cytometry/cytogenetics results from around these dates, I can help integrate them with these biopsy findings for a more complete picture.
1000731794.jpg
1000731793.jpg
These are aspirations results
Finding Sources
Searching PubMed
"myelodysplastic syndrome" AND "multilineage dysplasia"
These two aspiration reports are the matching bone marrow aspirates that go with the two trephine biopsies you shared earlier - the MRD numbers line up exactly (4190123 with the June biopsy, 4266145 with the August biopsy), which also resolves the identifier concern I flagged before: this is the same patient (Khursheed Ahmad/Khursheed Ah. Chauhan) presenting on two separate occasions about two months apart, not a data mix-up.
Aspirate-Biopsy Correlation, Visit by Visit
| Visit 1 (Earlier) — Aspirate Lab 679/26, dated 30/05/26 (reported 02/06/26) / Biopsy S-4507/26, 06/06/26 | Visit 2 (Later) — Aspirate Lab 1045/26, dated 03/08/26 / Biopsy S-6770/26, 08/08/26 | |
|---|---|---|
| MRD No. | 4190123 | 4266145 |
| Clinical details | Bicytopenia, reactive lymphocytes on PBF, macrocytosis with polychromasia | c/o Bicytopenia |
| Aspirate smear cellularity | Mildly hypercellular | Hypercellular |
| Trephine cellularity | Hypercellular for age | Hypocellular |
| Iron stores | Reduced | 4+ (markedly increased) |
| Blasts | 2% | 3% |
| M:E ratio (approx.) | ~1.1:1 (erythroid-rich) | ~1.75:1 |
| Erythroid % | 42% | 32% |
| Myeloid left shift (myelocyte+metamyelocyte+band) | 24% | 36% |
| Erythropoiesis | Normoblastic to mildly megaloblastic, erythroid hyperplasia, dyserythropoiesis (nuclear lobation, blebbing, karyorrhexis, sieve-like chromatin) | Normoblastic, dyserythropoiesis (nuclear lobation, blebbing, karyorrhexis) - no hyperplasia this time |
| Myelopoiesis | All stages present, dysmyelopoiesis | All stages present, mild dysmyelopoiesis, abnormally lobated "donut" neutrophils |
| Megakaryopoiesis | Adequate, pleomorphic megakaryocytes | Adequate on aspirate, but reduced + dysplastic on biopsy |
| Aspirate impression | Trilineage marrow, normoblastic-to-megaloblastic erythroid hyperplasia with dyserythropoiesis, dysplastic myeloid series, pleomorphic megakaryocytes | Trilineage hematopoiesis with erythroid and myeloid dysplasia |
| Advised | Trephine biopsy, vitamin B12/folate, MDS workup | Trephine correlation, vitamin B12/folic acid, MDS workup |
What the combined aspirate + biopsy picture shows
1. A consistent, reproducible trilineage dysplastic picture. Both aspirates - read independently by different pathologists, two months apart - describe the same core abnormality: dyserythropoiesis (abnormal nuclear lobation, cytoplasmic blebbing, karyorrhexis) plus dysmyelopoiesis (donut/abnormally lobated neutrophils) plus megakaryocyte pleomorphism. Both biopsies confirm dysplastic erythroid and myeloid elements, and the second biopsy adds dysplastic megakaryocytes. This reproducibility across two independent samplings strengthens rather than weakens the concern for a genuine myelodysplastic syndrome (MDS), most consistent with MDS with multilineage dysplasia in the WHO/ICC framework - Washington Manual of Medical Therapeutics; Goldman-Cecil Medicine.
2. Blast count remains low but is trending upward (2% → 3%). Both values stay well under the 5% threshold that would define MDS with excess blasts, so there is no aspirate/biopsy evidence yet of a shift toward acute leukemia. Still, an upward trend over two months plus the appearance of blasts on the second trephine (2-3%, whereas the first biopsy noted none) means this needs to be tracked serially rather than dismissed.
3. Cellularity is discordant between aspirate and biopsy, and this discordance is itself informative. At Visit 2, the aspirate smear was called "hypercellular," yet the trephine core biopsy from the same sitting was "hypocellular." This aspirate/biopsy mismatch is a recognized pattern in hypoplastic MDS - marrow involvement is patchy, so an aspirate needle can hit a cellular pocket while the core biopsy (which samples a broader, more representative area) shows the true patchy hypocellularity. The trephine is generally considered more reliable for cellularity assessment than the aspirate for exactly this reason. Falling erythroid percentage (42% → 32%) and reduced megakaryocytes on the second biopsy corroborate that the marrow is becoming globally less productive, not just showing a sampling artifact.
4. Iron stores jumped from "reduced" to "4+" (markedly increased). This is a notable change over just two months. The most common explanation is that the patient received red cell transfusions between visits (transfusional hemosiderosis), which would fit with ongoing bicytopenia/anemia. Ineffective erythropoiesis from evolving MDS can also cause iron loading independent of transfusion. This should be clarified with the transfusion history.
5. Increasing myeloid left shift (immature myeloid forms rising from 24% to 36% of the differential) alongside a falling erythroid fraction suggests the marrow's already-limited output is being redirected or is under stress, consistent with a marrow that is becoming progressively less effective rather than improving.
Overall Impression
Putting all four documents together, the trajectory over roughly two months is:
- Visit 1: Mildly hypercellular/hypercellular-for-age marrow with erythroid hyperplasia and mild trilineage dysplasia, low iron stores, 2% blasts - a picture that could initially be read as reactive/nutritional (megaloblastoid) change with superimposed dysplasia.
- Visit 2: Hypocellular trephine (despite a hypercellular aspirate smear), reduced/dysplastic megakaryocytes, falling erythroid proportion, rising myeloid immaturity, markedly increased iron stores, and a slight rise in blasts to 3%.
This evolution is most consistent with an evolving myelodysplastic syndrome, now trending toward a hypoplastic/hypocellular MDS phenotype, rather than a purely nutritional megaloblastic anemia. Both pathology teams independently recommended the same next steps - trephine correlation, vitamin B12/folate assay, and formal MDS workup - and given the interval changes, I would add:
- Cytogenetics/FISH and NGS mutation panel on the marrow (essential for WHO/ICC subtyping and IPSS-M risk stratification)
- Serial blast counts and cytopenia trend (CBC with differential) to catch any further increase early
- Transfusion history review to explain the iron store jump
- Repeat vitamin B12/folate levels if not already back, since both reports raised megaloblastic features that need to be excluded as a confounder
This is a case that should stay under close hematology follow-up given the trend, even though blast counts have not yet crossed into the excess-blast MDS category.
This is a shared conversation. Sign in to Orris to start your own chat.